164 related articles for article (PubMed ID: 21590790)
1. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
2. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
3. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
4. Monitoring late-onset toxicities in phase I trials using predicted risks.
Bekele BN; Ji Y; Shen Y; Thall PF
Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
[TBL] [Abstract][Full Text] [Related]
5. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
6. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
7. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
8. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
9. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
Zhao L; Lee J; Mody R; Braun TM
Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
[TBL] [Abstract][Full Text] [Related]
10. Sequential designs for phase I clinical trials with late-onset toxicities.
Cheung YK; Chappell R
Biometrics; 2000 Dec; 56(4):1177-82. PubMed ID: 11129476
[TBL] [Abstract][Full Text] [Related]
11. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
12. Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
Braun TM; Levine JE; Ferrara JL
Control Clin Trials; 2003 Dec; 24(6):669-81. PubMed ID: 14662273
[TBL] [Abstract][Full Text] [Related]
13. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
14. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities.
Braun TM
Stat Med; 2006 Jun; 25(12):2071-83. PubMed ID: 16217853
[TBL] [Abstract][Full Text] [Related]
15. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
16. How to design a dose-finding study using the continual reassessment method.
Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
[TBL] [Abstract][Full Text] [Related]
17. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
Ishizuka N; Ohashi Y
Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
[TBL] [Abstract][Full Text] [Related]
18. Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.
Huang B; Kuan PF
Biom J; 2014 Nov; 56(6):933-46. PubMed ID: 24895140
[TBL] [Abstract][Full Text] [Related]
19. The continual reassessment method for dose-finding studies: a tutorial.
Garrett-Mayer E
Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
[TBL] [Abstract][Full Text] [Related]
20. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Andrillon A; Biard L; Lee SM
J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]